UK venture fund launches with a life sciences research focus

Epidarex Capital announced its latest fund launch totaling £102 million ($128 million) that includes a commitment from the British Business Bank’s Enterprise Capital Funds program.

The fund, Epidarex Capital III UK, will invest in new life science companies from emerging research hubs across the U.K., including spinouts from highly regarded universities. The typical investments will range from £2 million to £5 million.

The Enterprise Capital Fund (ECF) program centers on early stage venture capital and since its inception has committed £1.36 billion to facilitate finance to 540 smaller U.K. high growth . . .

Continue Reading

Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available. Research articles require an Annual sub.

Get started

Related Articles

Back to top button

Start Your Days in the Know


Get fresh alts intel in your inbox with our FREE newsletter!

You have Successfully Subscribed!